A Deletion in the Gene for Glycoprotein IIb Associated with Glanzmann’s Thrombasthenia

Carol D. Burk,* Peter J. Newman,‡ Suzanne Lyman,§ Joan Gill,§ Barry S. Coller,|| and Mortimer Poncz*

*Division of Hematology, The Children’s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; ‡The Blood Center of Southeastern Wisconsin, Milwaukee, Wisconsin 53223; §Departments of Pediatrics and Anatomy and Cellular Biology, Medical College of Wisconsin, Milwaukee, Wisconsin 53223; and the ||Division of Hematology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, New York 11790

Abstract

The platelet fibrinogen receptor is composed of a complex of glycoproteins (GP) IIb and IIa on the surface of platelets. Deficient function of this receptor prevents normal platelet aggregation, resulting in Glanzmann’s thrombasthenia (GT). In this paper, we describe a black thrombathenic patient who is either homozygous or hemizygous for a deletion within the GPIIb gene. Initial Western blot analysis of platelet proteins from this patient did not detect any GPIIb, but did detect small amounts of GPIIIa of normal mobility. Quantitation of vitronectin receptor (VNR) demonstrated that this thrombathenic patient had ~1.5–2 times the number of these receptors per platelet compared with controls, a finding that has previously been noted in other thrombathenic patients with defects in GPIIb. Genomic Southern blot studies demonstrated a deletion in the GPIIb gene of ~4.5 kilobasepairs (kb). Analysis of the isolated GPIIb gene demonstrated that the deletion begins between two Alu repeats within intron 1 and ends in intron 9. Polymerase chain reaction (PCR) studies using platelet RNA and oligonucleotides directed to both the 5’ and 3’ ends of the GPIIb cDNA sequence easily detected GPIIb transcript, suggesting that the genomic deletion of exons 2–9 does not significantly decrease the level of the GPIIb mRNA. Sequence analysis of PCR-generated GPIIb cDNA showed that a cryptic AG splice acceptor sequence was being utilized, resulting in a transcript that contained a portion of introns 1 and 9, as well as having a deletion of exons 2–9. Unlike the GPIIb gene, the GPIIIa gene appears to be intact by Southern blot analysis. PCR studies using platelet RNA and oligonucleotides directed to the GPIIIa cDNA sequence demonstrated the presence of GPIIIa mRNA. In summary, the thrombathenic state in this patient appears to be due to a GPIIb gene deletion resulting in an abnormal transcript and no detectable platelet GPIIb. Platelet GPIIIa levels were secondarily low presumably due to the known instability of GPIIIa in the absence of GPIIb. (J. Clin. Invest. 1991. 87:270–276.) Key words: Glanzmann’s thrombasthenia • platelet • glycoprotein IIb • deletion

Introduction

The major fibrinogen receptor on the surface of activated platelets is a calcium-dependent heterodimeric complex of (GPIIb)1 glycoprotein IIb and GPIIIa (1–4). This receptor contains binding sites for von Willebrand factor, fibronectin, and vitronectin as well as fibrinogen (2–7). The cDNAs for near full-length GPIIb and GPIIIa have been cloned, and the encoded primary amino acid sequences deduced (8–12). Northern blot analysis of RNA from various tissues as well as immunologic and related studies have demonstrated that GPIIb is normally expressed only in platelets, whereas GPIIIa is also present on other tissues, where it is complexed with the α, subunit to form the vitronectin receptor (α,β) (VNR) (13–16). It is interesting that gene localization studies with the GPIIb and GPIIIa cDNAs have demonstrated that these genes are within ~250 kilobasepairs (kb) of each other on the long arm of chromosome 17 (17). Whether this unusual proximity for two concurrently expressed genes is related to their expression in platelets is not presently known.

The GPIIb/IIIa complex is one of the integrins, a family of heterodimeric receptors that are involved in cell–cell and cell–matrix interactions (15, 16). Many of these receptors bind to an overlapping group of extracellular adhesion proteins, and this binding can often be competitively inhibited by Arg-Gly-Asp-containing synthetic peptides (7, 18–21). A number of unique α (GPIIb-like) chains complex with a smaller number of more ubiquitous β (GPIIIa-like) chains to form these receptors. Sequence analysis of the cDNAs for a number of the α chains have been published, and the encoded proteins share ~30–70% amino acid identity (9, 22–29). The mature α chains are ~140 kD and many of these α chains consists of two disulfided-linked subchains. In an analogous fashion, sequence analysis of the cDNAs of a number of the β chains has also been accomplished, and the encoded proteins also share amino acid homology (10, 11, 30–32). The β proteins are single chains of ~95 kD, and contain four cysteine-rich domains. Unlike the close proximity of GPIIb and GPIIIa on chromosome 17, the genes for other α and β chains are fairly well distributed within the human genome (12, 33, 34).

Glanzmann’s thrombasthenia is a rare autosomal recessive bleeding disorder in which platelets fail to aggregate during hemostasis secondary to disorders affecting the GPIIb/IIIa receptor (35–39). Patients may have a qualitative and/or a quantitative defect in their GPIIIa/IIIa receptor. In most of these patients, the levels of GPIIb and IIIa are coordinately decreased. It is unknown if this coordinate reduction of GPIIb

Abstract

The platelet fibrinogen receptor is composed of a complex of glycoproteins (GP) IIb and IIa on the surface of platelets. Deficient function of this receptor prevents normal platelet aggregation, resulting in Glanzmann's thrombasthenia (GT). In this paper, we describe a black thrombathenic patient who is either homozygous or hemizygous for a deletion within the GPIIb gene. Initial Western blot analysis of platelet proteins from this patient did not detect any GPIIb, but did detect small amounts of GPIIIa of normal mobility. Quantitation of vitronectin receptor (VNR) demonstrated that this thrombathenic patient had ~1.5–2 times the number of these receptors per platelet compared with controls, a finding that has previously been noted in other thrombathenic patients with defects in GPIIb. Genomic Southern blot studies demonstrated a deletion in the GPIIb gene of ~4.5 kilobasepairs (kb). Analysis of the isolated GPIIb gene demonstrated that the deletion begins between two Alu repeats within intron 1 and ends in intron 9. Polymerase chain reaction (PCR) studies using platelet RNA and oligonucleotides directed to both the 5' and 3' ends of the GPIIb cDNA sequence easily detected GPIIb transcript, suggesting that the genomic deletion of exons 2–9 does not significantly decrease the level of the GPIIb mRNA. Sequence analysis of PCR-generated GPIIb cDNA showed that a cryptic AG splice acceptor sequence was being utilized, resulting in a transcript that contained a portion of introns 1 and 9, as well as having a deletion of exons 2–9. Unlike the GPIIb gene, the GPIIIa gene appears to be intact by Southern blot analysis. PCR studies using platelet RNA and oligonucleotides directed to the GPIIIa cDNA sequence demonstrated the presence of GPIIIa mRNA. In summary, the thrombathenic state in this patient appears to be due to a GPIIb gene deletion resulting in an abnormal transcript and no detectable platelet GPIIb. Platelet GPIIIa levels were secondarily low presumably due to the known instability of GPIIIa in the absence of GPIIb. (J. Clin. Invest. 1991. 87:270–276.) Key words: Glanzmann's thrombasthenia • platelet • glycoprotein IIb • deletion

Introduction

The major fibrinogen receptor on the surface of activated platelets is a calcium-dependent heterodimeric complex of (GPIIb)1 glycoprotein IIb and GPIIIa (1–4). This receptor contains binding sites for von Willebrand factor, fibronectin, and vitronectin as well as fibrinogen (2–7). The cDNAs for near full-length GPIIb and GPIIIa have been cloned, and the encoded primary amino acid sequences deduced (8–12). Northern blot analysis of RNA from various tissues as well as immunologic and related studies have demonstrated that GPIIb is normally expressed only in platelets, whereas GPIIIa is also present on other tissues, where it is complexed with the α, subunit to form the vitronectin receptor (α,β) (VNR) (13–16). It is interesting that gene localization studies with the GPIIb and GPIIIa cDNAs have demonstrated that these genes are within ~250 kilobasepairs (kb) of each other on the long arm of chromosome 17 (17). Whether this unusual proximity for two concurrently expressed genes is related to their expression in platelets is not presently known.

The GPIIb/IIIa complex is one of the integrins, a family of heterodimeric receptors that are involved in cell–cell and cell–matrix interactions (15, 16). Many of these receptors bind to an overlapping group of extracellular adhesion proteins, and this binding can often be competitively inhibited by Arg-Gly-Asp-containing synthetic peptides (7, 18–21). A number of unique α (GPIIb-like) chains complex with a smaller number of more ubiquitous β (GPIIIa-like) chains to form these receptors. Sequence analysis of the cDNAs for a number of the α chains have been published, and the encoded proteins share ~30–70% amino acid identity (9, 22–29). The mature α chains are ~140 kD and many of these α chains consists of two disulfided-linked subchains. In an analogous fashion, sequence analysis of the cDNAs of a number of the β chains has also been accomplished, and the encoded proteins also share amino acid homology (10, 11, 30–32). The β proteins are single chains of ~95 kD, and contain four cysteine-rich domains. Unlike the close proximity of GPIIb and GPIIIa on chromosome 17, the genes for other α and β chains are fairly well distributed within the human genome (12, 33, 34).

Glanzmann's thrombasthenia is a rare autosomal recessive bleeding disorder in which platelets fail to aggregate during hemostasis secondary to disorders affecting the GPIIb/IIIa receptor (35–39). Patients may have a qualitative and/or a quantitative defect in their GPIIIa/IIIa receptor. In most of these patients, the levels of GPIIb and IIIa are coordinately decreased. It is unknown if this coordinate reduction of GPIIb...
and GPIIIa results from decreased protein stability of nonduplexed GPIIb or GPIIIa as demonstrated in transient expression studies when the cells are transfected with only one of the two expression vectors (40), or is due to coordinate regulation of expression of these two physically close genes (12).

The specific molecular basis of the various thrombasthenic phenotypes has yet to be elucidated. Molecular studies of these patients may correlate with clinical differences between those with defects in GPIIb and those with defects in GPIIIa. Also, these studies may reveal the biological significance of the close association of these two genes on chromosome 17. In this paper, we describe a black patient with severe Glanzmann's thrombasthenia whose bleeding diathesis appears to be secondary to a deletion within the gene for GPIIb.

Methods

Clinical history. The patient is an adopted black teenage male (K.W.) with type I Glanzmann's thrombasthenia. The initial diagnosis was established by absence of platelet aggregation after stimulation with epinephrine, collagen, and ADP. Clinically, he has moderate bleeding manifested by moderate to severe epistaxis and gingival bleeding, but requires only rare platelet transfusions. The other subjects shown in Fig. 2, A and B, include a normal volunteer and two other unrelated patients with thrombasthenia.

Polyclonal and monoclonal antibodies. Polyclonal antisera specific for human platelet GPIIb was raised by immunizing rabbits with a mixture of nonreduced and reduced GPIIb that had been affinity purified by AP3-Sepharose chromatography (41). The anti-GPIIb antibodies were affinity-purified from the antisem on immobilized GPIIb, and specificity was verified by immunoprecipitation and immunochemical reaction with monoclonal antibody PMI-1, specific for GPIIb (42), was kindly provided by Dr. Mark Ginsberg, Scripps Institute, La Jolla, CA. Murine monoclonal antibodies LM 609 and LM 142, specific for the VNR complex and VNR alpha-subunit, respectively, (43, 44) were a generous gift of Dr. David Cheresh, Scripps Institute, La Jolla, CA. The affinity-purified polyclonal rabbit antibody for PECAM-1 has been previously described (45).

Platelet membrane glycoprotein analysis. Platelets from both normal control individuals and thrombasthenic K.W. were prepared by differential centrifugation of acid citrate dextrose (ACD) anticoagulated whole blood as previously described (46). Platelets were washed three times in modified Tyrodes buffer, pH 6.8, and then lysed in a solution of 2% (wt/vol) SDS, 5% (vol/vol) β-mercaptoethanol, and 50 mM Tris, pH 6.8. 75 μg of total protein per lane was electrophoresed through a 9% (wt/vol) SDS polyacrylamide gel, and the proteins transferred to an Immobilon (polyvinylidene difluoride) membrane (Millipore Continental Water Systems, Bedford, MA) for subsequent Western blot analysis. The GPIIb and GPIIIa content of each platelet lysate was determined simultaneously on the same blot by coincubation of the membranes with the anti-GPIIb murine monoclonal antibody PMI-1 and the rabbit anti-GPIIb polyclonal antibody. Equal protein loading of samples was assessed by coincubation of the blots with affinity-purified antibody specific for PECAM-1, the levels of which are unaffected by the thrombasthenic phenotype (unpublished observation). Primary antibody binding was detected using a mixture of alkaline phosphatase-conjugated goat anti-rabbit and goat anti-mouse IgGs in conjunction with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium salt substrate pair.

Platelet VNR quantitation. Blood from the patient and two controls was drawn and anticoagulated with ACD formula A (ACD-A; 1.5 ml for 8.5 ml blood) in Milwaukee, and then coded and shipped overnight to Stony Brook. Blood from an additional control was obtained in Stony Brook immediately after the samples arrived. The platelet counts in the samples were increased by preparing platelet-rich plasma (PRP), adding 0.1 vol of ACD-A to the PRP, centrifuging the PRP to pellet the platelets (~16,000 g min at 22°C), removing some of the supernatant plasma, and then resuspending the pellets to achieve platelet counts of ~2 X 10^7/ml. Antibody LM 142, directed against the VNR alpha-subunit, and antibody LM 609, directed against the VNR complex (αβ1), were purified by protein G affinity chromatography and radiolabeled with ^125I using immobilized iodogen ( Pierce Chemical Co., Rockford, IL). Aliquots (0.2 ml) of the concentrated PRP were incubated with 5 μl of buffer (0.15 M NaCl, 0.01 M Tris HCl, pH 7.4) for 30 min and then with one of the radiolabeled antibodies for 90 min at 22°C. Platelet-bound antibody was then separated from free antibody by centrifugation through 30% sucrose. Nonspecific binding was determined by substituting ascites fluid containing the appropriate antibody for the 5 μl of buffer in the first incubation step. Two different concentrations of each antibody were used: ~110 ng/ml (range, 108-113 ng/ml) and ~313 ng/ml (range, 305-321 ng/ml) for LM 142, and ~129 ng/ml (range, 112-147 ng/ml) and ~396 ng/ml (range, 388-405) for LM 609. Previous studies indicated that the Kd for LM 142 is ~85 ng/ml, and the Kd for LM 609 is ~109 ng/ml; at concentrations ~10 times the Kd, the mean (±SD) number of LM 142 molecules that bound to normal platelets was 22±6 (n = 10), and the number of LM 609 molecules that bound was 33±11.

Southern blot analysis. DNA was prepared from whole blood as previously described (47). A 20-μg aliquot was digested at 37°C with 30–50 U of each restriction endonuclease using buffers and conditions recommended by the suppliers. Fragments were separated by electrophoresis through 0.6% agarose and transferred to Gene Screen Plus membrane (New England Nuclear, Boston, MA). Hybridizations and washing were carried out at 65°C according to standard conditions suggested by the manufacturer: A 3.3-kb full-length GPIIb cDNA (9), and the 5’ and 3’ Eco RI fragments of the GPIIb cDNA (11), comprising the full-length cDNA, were used as probes for the initial genomic Southern blot analyses. A 2.4-kb Bam HI/Bgl II GPIIIa genomic fragment, containing exons 5–12 (Fig. 2 C) (48), was used as a probe to further localize the deletion on genomic Southern blot analysis. Probes were radiolabeled with α-32P dCTP using random oligo primers and Klenow as described previously (49).

Construction and screening of the thrombasthenic genomic library. Using 110 μg of genomic DNA isolated from the thrombasthenic patient, a lambda genomic library was constructed (50). The DNA was partially digested with Sau III. Fragments from 15 to 24 kb in length were selected on a sucrose gradient, ligated to EMBL 3A arms, and packaged using the GigaPack Plus Cloning System (Stratagene, La Jolla, CA), and the resultant phage were used to infect NM539 bacteria. Screening of the library with radiolabeled GPIIb cDNA was as previously described (49).

Characterizing the deleterional breakpoint. Positive clones were plaque-purified, and the insertes were characterized by restriction analysis and Southern blotting studies using radiolabeled GPIIb cDNA probe. An Sst I restriction fragment which was anticipated to contain the deleterional breakpoint was isolated and subcloned into M13 mp18 phage. Clones containing the insert in complementary orientations were identified using an S1 nuclelease protection assay (51). In addition, S1 nuclease protection assays were performed between these single-stranded clones and the complementary normal 4.8-kb Bam HI fragment that contains exons 5–13 (Fig. 2 C) (51) to localize the deleterional breakpoint within the Sst I fragment.

Sequence analysis was performed using the Sanger method (52) and the Sequenase enzyme protocol (United States Biochemical Corp., Cleveland, OH). The antisense 15 nucleotide oligonucleotide (TGC-GAGAACAATAC) used as a primer for sequence analysis across the deleterional breakpoint is complementary to bases 1108–1122 of the full-length GPIIb cDNA and is located within exon 12 (48).

Platelet mRNA studies. Total cellular RNA was prepared from human platelets, and specific regions of mRNA were reverse transcribed into cDNA and then amplified using the polymerase chain reaction (PCR) technique as previously described (46, 53). Oligonucleotide primers were used at final concentrations of 200–500 nM except for reaction tubes containing more than one primer pair (multiplex PCR),
in which all primer concentrations were limited to 100 nM to avoid artifacts associated with primer complementarity. PCR primers 1–4 correspond to sequences of GPIib cDNA (9), whereas primers 5 and 6 correspond to sequences of GPIIIa cDNA (10). Following amplification, PCR reactions products were resolved on 10% agarose gels (FMC Corp., Rockland, ME) recovered using GENECLEAN (Bio 101 Co., La Jolla, CA), and sequenced directly using T7 DNA polymerase (Sequenase™; United States Biochemical Corp., Cleveland, OH) according to manufacturer’s recommendations. In some instances cDNA fragments were blunt-end ligated into the Eco RV-cut plasmid vector pGEM-5Zf for restriction site and DNA sequence analyses.

Oligonucleotides used for these studies include the GPIib oligonucleotides 1 (GGCCAGAGCTGTGCTCCACTGCG) for GPIib, bases 4–26 (sense), 2 (CCATATACGAGCCGGC) for GPIib, bases 1037–1015 (antisense), 3 (GAGCTGAGATGAGCGACGAC) for GPIib, bases 1988–2011 (sense), 4 (CAGGAGGCGACGCACCCAC) for GPIib, bases 2821–2797 (antisense), 5 (CATGCTGTGCCTGGTGCTG) for GPIIa, bases 161–183, and 6 (CACCTGGTCAGTTAGCGTCAGCAC) for GPIIIa, bases 698–674 (antisense). These primers are schematically shown at the top of Fig. 4.

**Results**

**Immunoblot analysis of GPIib and GPIIIa.** The thrombasthenic phenotype of patient K.W. was confirmed by immunoblot analysis using a mixture of anti-GPIib, anti-GPIIIa and anti-PECAM-1 antibodies. As shown in Fig. 1, K.W. had undetectable levels of GPIIIa. Significantly, GPIIIa was present at approximately 1–5% of normal levels, and that which was present comigrated with normal GPIIIa. That approximately equal amounts of protein were loaded in each lane was demonstrated by immunostaining with anti-PECAM-1, which is known to be present in normal amounts in thrombasthenic platelets (Newman, P.J., unpublished observations), consistent with a primary defect in GPIIib, with GPIIIa levels being secondarily affected.

**Platelet VNR quantitation.** The results of the antibody LM 142 and LM 609 binding studies are presented in Table I. The values for the control samples drawn in Milwaukee were similar to those of the fresh sample drawn in Stony Brook, suggesting that the lag time involved in transporting the samples did not significantly affect the results. The values for the higher doses of antibody binding to control platelets were also similar to the values previously obtained using near-saturated concentrations of the antibodies with other normals drawn fresh at Stony Brook (LM 142 = 22±6 molecules per platelet, and LM 609 = 33±11 molecules per platelet).

Each of the values for the patient’s platelet exceeded the highest value for any of the controls; the increases in binding for both antibodies were concordant (LM 142, ~180% control; LM 609, ~200%). These results indicate that at least some of the GPIIIa identified by immunoblot analysis is associated with the α subunits to form VNR. Since this indicates that the patient’s GPIIIa is able to complex with an α subunit normally, it suggests that the patient’s defect would be in the GPIib unit. Analysis of other patients with thrombasthenia have shown that in those patients with a GPIIIa defect, that the number of anti-VNR antibody bound per platelet is similarly increased in patients whose defects are in GPIlib (54–56).

**Southern blot analysis of the genes for GPIib and GPIIIa.** Southern blot analyses of genomic DNA from patient K.W., a normal control, and two additional thrombasthenic patients were performed using restriction endonucleases Hind III, Sst I, and Bam HI, and compared with blots of a panel of normal controls. Blots hybridized with radiolabeled full-length GPIIIa cDNA demonstrated completely normal banding patterns in all four patients (data not shown). The identical blots were also hybridized with radiolabeled full-length GPIib cDNA (Fig. 2, A and B). The normal control and the two other thrombasthenic patients demonstrated the anticipated restriction pattern. However, patient K.W. had an absence of a 13.9-kb Hind III fragment with the appearance of a new 9.4-kb fragment (Fig. 2 B), an absence of a 9.6-kb Sst I fragment with the appearance of a new 5.0-kb fragment (Fig. 2 A), and an absence of a 4.8-kb Bam HI fragment (data not shown). These findings are consistent with a homozygous or hemizygous 4.5–5.0 kb deletion encompassing a major portion of the coding regions of the absent Bam HI fragment and localizes the deletion to a region beginning downstream of exon 1 at its 5’ end and the exon 13–18 cluster at its 3’end in Fig. 2 B. Further localization of the deletion was accomplished by hybridizing the same Hind III/Bam HI blot to radiolabeled 2.4-kb Bam HI/Bgl II genomic GPIib fragment (which includes exon 5–12 in Fig. 2 B). Results of this experiment (data not shown) revealed that the large 9.4-kb Hind III fragment is present, and the 4.8-kb Bam HI fragment is absent. A new 9.8-kb Bam HI fragment was now detected that was not appreciated with the GPIib cDNA probe. This new band must

| Table I. Quantitation of Platelet Vitronecrotic Receptor Subunits |
|-----------------|-----------------|-----------------|
| Patient         | Anti-VNR α chain antibody | Anti-VNR complex antibody |
|                 | low Ab | high Ab | low Ab | high Ab |
| Controls:       |        |        |        |        |
| Milwaukee 1     | 21*    | 37     | 33     | 57     |
| Milwaukee 2     | 21     | 31     | 31     | 31     |
| Stony Brook     | 25     | 21     | 36     | 58     |
| Mean            | 22     | 30     | 33     | 49     |
| K.W.:           | 39     | 53     | 60     | 105    |
| Percentage of control | 157   | 252   | 167   | 182    |

* Antibody molecules bound per platelet.
result from a deletion of the Bam HI site near exon 5, and further localizes the deletion to within a region that extends downstream of exon 1 to near exon 12 in Fig. 2 C.

In order to define the deletion endpoints a partial Sau IIIa genomic library of the patient's DNA was constructed and screened. Three positive clones were isolated after screening a total of 400,000 plaques with the full-length GPIIb cDNA probe. Restriction analysis demonstrated that all three clones included a 5.3-kb Sst I fragment. This fragment would be expected to encompass the deleted area, and represents a 4.6-kb shortening of the normal Sst I fragment shown in Fig. 2 B.

Initial localization of the deletional breakpoint was done using an S1 nuclease protection assay between single-stranded M13 phage containing the patient's truncated Sst I fragment and single-stranded M13 phage containing the normal 4.8-kb Bam HI genomic fragment which contains exons 5 through 13 in Fig. 2 C. A fragment of ~ 3.3 kb was protected, placing the 3' deletion breakpoint within the cluster of exons 8–12 (data not shown).

Sequence analysis across the deletional breakpoint was accomplished using single-stranded DNA of the 5.3-kb Sst I thrombasthenic insert in M13 mp18 phage as template and a complementary antisense oligonucleotide to a region of exon 12 (48) as primer as described in Methods. The upstream breakpoint of the deletion is in intron 1, and is 483 bp 3' to exon 1 and is within the 5' end of the second of a pair of direct Alu repeats (57) (Fig. 3). The only difference between the published normal sequence and K.W.'s in this region is the length of the poly A region at the end of the Alu repeat, which is 20 in the normal and 11 in K.W. (asterisk in Fig. 3). This difference may represent a polymorphism. At the 3' end, the deletion ends in intron 9, and is 69 bp 5' to the start of exon 10, and 1551 bp 5' to an Alu repeat in intron 12 (48). Between the two breakpoints is an additional 10 bp that has only limited homology with either the normal 5' or 3' GPIIb sequence (dash-boxed in Fig. 3). The deletion includes 2.0 kb of intron 1 that has yet to be sequenced (48), so that the exact size of the deletion is not known but is estimated to be 4.5 kb.

PCR analysis of normal and K.W. platelet RNA transcripts.
To assess the effect on transcription and mRNA processing of this major deletion in the GPIIb gene, we initially attempted without success to analyze platelet GPIIb and GPIIIa mRNA by Northern blot analysis (data not shown). Platelets contain only small amounts of residual RNA, and the inability to demonstrate the presence of GPIIb and GPIIIa RNA might simply reflect this technical problem in obtaining sufficient RNA. We, therefore, used the more sensitive approach of reverse transcribing the RNA into single-stranded complementary DNA followed by PCR amplification (46, 53). This approach allowed us to analyze whether there is detectable GPIIb mRNA in K.W.'s platelets and to study the effect of the genomic deletion on intron processing. Several primer pairs, delineated in Methods, were used. The results of studies with normal and K.W.'s total platelet RNA using the two primer pairs for GPIIb mRNA and the one pair for GPIIIa that are schematically illustrated at the top of Fig. 4 are discussed below.

Primers 3+4 normally result in an amplified DNA segment of 833 bp and 5+6 normally result in an amplified DNA segment of 537 bp. PCR analysis of the patient's platelet RNA with both of these oligonucleotides demonstrate that both GPIIb and GPIIIa mRNAs are detectable in K.W.'s platelet RNA with the same size and quantity of final PCR product as in the normal control (Fig. 4 A). Primer pair 1+2 was
Figure 4. PCR analysis of cDNA derived from total platelet RNA. (A) A normal control (C) was compared with patient K.W. A multiplex analysis with GPIIb primers 3 + 4 and with GPIIIa primers 5 + 6 are shown in the middle set of lanes of the agarose gel. At the right are two lanes with GPIIb primers 1 + 2. The sites and orientation of these primers are shown in schematic form at the top of the figure. At the left is a standard size marker lane (S) of lambda phage digested with Hind III and φ X phage digested with Hae III. (B) Schematic representation of the normal sequence in the region of interest of the GPIIb gene with the DNA deleted shown as the hatched on the top line. Exons are indicated as open numbered boxes. The 5'- and 3'-flanking regions and the introns are indicated as a line. Intron 1 is shown as a heavier black line and intron 9 is shown as a heavier grey line. The cryptic splice acceptor site is indicated as an encircled AG. The breakpoints of deletion are indicated by the break in the introns bordered by two short diagonally placed lines, and the actual DNA sequence deleted is shown under a diagonally shadowed region. Below is a schematic representation of the GPIIb gene in K.W. in this same region, and beneath this is a schematic representation of the initial RNA transcript of this partially deleted gene in the region of interest, with the breakpoint point of the deletion indicated. At the designed to amplify a region surrounding the deletion indicated from the genomic cloning experiments, with primer 1 located within exon 1 of the GPIIb gene, and primer 2 corresponding to a region on the antisense strand within exon 12. The PCR product expected from this primer pair is 1,033 bp, and this band is observed in studies with normal platelet RNA (Fig. 4A). In light of the fact that exons 2–9 are deleted in the genome of K.W., we expected a 296-bp PCR product using K.W.’s platelet RNA as starting material, assuming that exon 1 spliced to the next normal splice acceptor site which is found preceding exon 10. Unexpectedly, the PCR product obtained was 580 bp. Sequence analysis demonstrated that this 580-bp cDNA band encoded parts of intron 1 and 9, consistent with the utilization of a cryptic AG splice acceptor located within a pyrimidine-rich region of intron 1 (48) (circled in Figs. 3 and 4B). This splice acceptor site probably becomes exposed due to secondary structure modifications in the heteronuclear GPIIb RNA transcribed from the deleted GPIIb gene. Thus a pseudogene is formed that contains a portion of introns 1 and 9 as well as all of exon 10 (Fig. 4B). The resulting GPIIb mRNA has an in-frame TAA termination codon 26 triplets downstream from the end of exon 1 (dot overlined in Fig. 3), resulting in a very truncated GPIIb protein. Even if sufficient GPIIb mRNA reaches the cytoplasm in the developing megakaryocyte, no full-length GPIIb product would be available to complex with the GPIIIa.

Discussion

Although previous studies suggest that Glanzmann’s thrombasthenia is due to a heterogeneous group of defects, the molecular basis for this heterogeneity has only begun to be defined on a molecular level. It is very likely that this disease will prove to be heterogeneous with many different mutations being defined in different ethnic groups and in patients with different clinical severity much as has already been demonstrated with the thalassemias (58). The classical division into the two categories of severely GPIIb/IIIa-deficient patients (type I) and those less deficient (type II) will be replaced by a precise definition of defects and correlation with phenotype. Recently, a patient heterozygous for an insertion in the GPIIIa gene has been reported (59). In this report, we describe a black thrombosthenic patient homozygous or hemizygous for a 4.5-kb deletion in the 5' region of the GPIIb gene. This deletion eliminates exons 2–9. Because natural relatives of this adopted subject are not available, further family studies could not be done to distinguish between the two possibilities.

As noted previously, the GPIIb gene is rich in Alu repeats, having at least 10 repeats distributed throughout its 17-kb sequence (48). All of these repeats are oriented in the same direction. At its 5' end, the deletion in K.W. occurs within a direct Alu repeat. However, most deletions for which the end-points of the breakpoint have been defined (e.g., the thalassemias [58]) do not involve Alu repeats. The fact that only one end of this patient's deletion occurs within a direct Alu repeat suggests that a nonhomologous crossover involving Alu repeats could not have caused this patient's deletion.

The large deletion in the GPIIb gene in K.W. results in an abnormal transcript that is missing exons 2–9, but contains...
portions of introns 1 and 9. This RNA is processed in the nucleus, using the normal exon 1 splice donor and a cryptic splice acceptor site in intron 1 to form a GPIIb mRNA species that is missing exons 2–9 and portions of introns 1 and 9 as well as exon 1 and exons 10–30. This mRNA species is sufficiently stable as to yield PCR-amplifiable GPIIb cDNA fragment from platelet total RNA. Unfortunately, while the amount of total RNA that can be isolated from platelets is sufficient for demonstrating a qualitative defect in K.W.‘s GPIIb mRNA, it is insufficient to quantitate the relative level of his GPIIb mRNA beyond stating that this mRNA species was present in platelets in sufficient amounts to be detectable by PCR amplification.

In contrast to the GPIIIa gene in this patient, the GPIIIa gene appears intact. Within the limitations of restriction endonuclease mapping of genomic DNA, the GPIIIa gene does not appear to have a deletion or rearrangement. Transcription from this gene has been shown by PCR analysis for GPIIIa using the patient’s platelet RNA. This mRNA is translated into GPIIIa with normal mobility as demonstrated on Western blot analysis. However, the level of this platelet GPIIIa protein is only 1–5% of normal. This low level of GPIIIa expression is most likely due to instability of unduplexed GPIIIa as shown by both pulse-chase studies of human megakaryocytes and megakaryocyte-like cell-lines (40), and by transient expression studies of recombinant GPIIb and IIIa in COS cells where transfection of either GPIIb or IIIa alone did not result in any surface expression, while cotransfection studies resulted in completion of GPIIb maturation and the expression of the GPIIb/IIIa complex on the cell surface (60). A small portion of platelet GPIIIa protein does form stable duplexes with VNR(61, 62). As in other patients with a deficiency in GPIIb, newly synthesized GPIIIa complexes with the small internal pool of VNR(61, 62), resulting in an increased level of VNR on the platelet surface, rescuing the 1–5% of GPIIIa molecules observed in such platelets. To explain why patients with defects in GPIIb may have an increase in platelet VNR, one can postulate that GPIIIb and VNR normally compete for a pool of GPIIIa molecules, and those GPIIIb and VNR molecules that fail to complex with a GPIIIa molecule are proteolytically digested. If GPIIb synthesis is impaired, then there will be fewer GPIIIb molecules to compete for GPIIIa, and thus it is more likely that the VNR(61, 62) molecules synthesized will join with GPIIIb molecules and be transported to the platelet membrane as VNR. Thus, the small amount of GPIIIa seen on the Western blot may be due solely to the presence of GPIIIa within the platelet VNR or be due in part to residual unduplexed cytoplasmic GPIIIa.

Acknowledgments

The authors thank Dr. M. Ginsberg and Dr. D. Chersh for their generous contributions of antibody reagents, Padmini Malladi and Dr. Eric Rappaport for excellent technical advice, and Dr. Saul Surrey and Dr. Elias Schwartz for useful discussions during the preparation of this manuscript.

This work was supported by grants from the National Institutes of Health (HL-40387, HL-07439, HL-38166, and HL-19278) and the March of Dimes.

References


is an invertebrate integrin that, like the fibronectin receptor, becomes localized to muscle attachments. Cell. 51:929–940.


